Latest Rosiglitazone Stories

ST. PAUL, Minn., April 12, 2011 /PRNewswire/ -- According to a new pharmacy benefit study, a point-of-sale automated electronic safety edit, designed to require provider prior authorization (PA) for members who have a rosiglitazone claim with concurrent use of insulin or nitrate (CIN), potentially decreased members' risk for myocardial ischemia. The study will be presented at the Academy of Managed Care Pharmacy's 23rd Annual Meeting in Minneapolis, Minn. by Prime Therapeutics (Prime), a...

NEW YORK, April 5, 2011 /PRNewswire/ -- The latest news on the much publicized Avandia Settlement's is: there is no news. After a Bloomberg report made public last summer that many of the Avandia suits were coming to a settlement range of approximately $86,000.00 per suit, no new news has come into the market. This has left many suffering Avandia plaintiffs with more confusion -and concern- when they will actually get their settlement money. This has led to many Avandia Plaintiffs to seek...

Research: Comparative cardiovascular effects of thiazolidinediones: Systematic review and meta-analysis of observational studiesA new study published on bmj.com today adds to mounting evidence that rosiglitazone - a drug used to treat type 2 diabetes - is associated with an increased risk of major heart problems.It finds that rosiglitazone is associated with significantly higher odds of congestive heart failure, heart attack and death compared with a similar drug (pioglitazone).Rosiglitazone...

The prevalence of type 2 diabetes is dramatically increasing throughout the world. Insulin resistance is a hallmark of type 2 diabetes, and it most often precedes the onset of hyperglycemia and predicts development of type 2 diabetes. At present, thiazolidinediones (TZD), the agonists of the peroxisome proliferators-activated receptor γ, are the main agents to improve insulin sensitivity in the liver, adipose tissue, and skeletal muscle, thus improving glycaemic control in patients with...

Johns Hopkins researchers examine newest medications, find they come up shortAn inexpensive type 2 diabetes drug that has been around for more than 15 years works just as well and has fewer side effects than a half-dozen other, mostly newer and more expensive classes of medication used to control the chronic disease, new Johns Hopkins research suggests.In their report, published online March 14 in the journal Annals of Internal Medicine, the Hopkins team found that metformin, an oral drug...

FAIRFIELD, N.J., Feb. 16, 2011 /PRNewswire/ -- The Lawsuit Settlement Funding Co., Legal-Bay LLC, announced that applications for Avandia pharmaceutical "lawsuit funding" were up over 500% in the month of January alone. The Lawsuit Settlement Funding Co. attributed the increased activity to their newly launched web-site: lawsuitssettlementfunding.com, which was announced on Jan. 12, 2011. Legal-Bay LLC, was already an industry leader in the pre-settlement funding for Avandia...

The Avandia lawyers at Onder, Shelton, O'Leary & Peterson, LLC have created a web site providing information about Avandia and how it has been linked to tens of thousands of heart attacks and strokes and the latest news on Avandia lawsuits Saint Louis, MO (Vocus) November 15, 2010 The law firm of Onder, Shelton, O'Leary & Peterson, LLC has launched a new website dedicated to providing information about Avandia heart attack and stroke lawsuits and are offering a free Avandia...

DEERFIELD, Ill. and LONDON, Sept. 23 /PRNewswire/ -- Following today's announcements by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for rosiglitazone in the U.S. and Europe, Takeda Pharmaceuticals North America, Inc. and Takeda Pharmaceuticals Europe Limited ("Takeda") underscore the company's commitment to ACTOS(®) (pioglitazone HCl) and ACTOS-containing medications, and to the millions of people living with type 2 diabetes. As this news may...

European regulators say that widely-used diabetes drug Avandia should be pulled from the market, but U.S. officials have allowed it to stay. The U.S. Food and Drug Administration in Washington and the European Medicines Agency (EMA) said in separate statements that they agreed on the risks associated with the drug but had reached different conclusions on action. Avandia was once Glaxo's second-biggest selling drug, but sales have dropped in recent years. "The decisions are not...

LONDON, Sept. 23 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE and LSE: GSK) confirms that following a review of Avandia® (rosiglitazone maleate) by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), each agency has today announced their individual regulatory decisions and the resulting actions. In the European Union*, the EMA has suspended the marketing authorization for all rosiglitazone-containing medicines (Avandia, Avandamet® and Avaglim®)....